4 min.Read

Indian Pharma Market Highlights

November 12, 2018

Indian Pharma Market highlights for the month of October 2018, brought to you by AIOCD Pharma Softech Awacs.

[su_dropcap style="flat"]T[/su_dropcap]he Indian Pharma Market (IPM) is back to double digit growth of 12.2%, compared to single digit growth in August and September, 2018.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

Topics

What pharma marketers get wrong about digital

Career – What Makes Us Tick?

Indian Pharma Market Highlights

Free Membership Required

Shakul Srivastava has been appointed as Senior Vice President at Indian Immunologicals Limited.

The Rx–Outcomes Dichotomy: India Has Iron Tablets. Why Does Anaemia Persist?

10 Years of Pharma M&A — Who’s Really Benefited?

What’s Killing Patients? Cancer or Rigged Drug Prices?

A Tale of Two Cities: Peptides and Prescriptions

Topics

Shakul Srivastava has been appointed as Senior Vice President at Indian Immunologicals Limited.

The Rx–Outcomes Dichotomy: India Has Iron Tablets. Why Does Anaemia Persist?

10 Years of Pharma M&A — Who’s Really Benefited?

What’s Killing Patients? Cancer or Rigged Drug Prices?

A Tale of Two Cities: Peptides and Prescriptions

Trust Is Pharma’s Fulcrum: Are We Getting the Basics Right?

The $1.5 Billion Question in Hyderabad: Orbicular, Peptides and the PE Re-Rating of Indian Complex Generics

Medical Reps—Lessons From The West: The Old Model is Dead

Related Articles

Can India Pivot From Low-Cost Medical Tourism to Trusted Medical Value Travel?

Oracle Debacle – Midlife Reinvention is an Al Generated Orwellian Lie

Strategic Communications for Healthcare Brands

Fostering Thought leadership in Healthcare

Sales View – On-the-Go Information, Insights & Learning for Pharma Professionals

Company

Headlines

Shakul Srivastava has been appointed as Senior Vice President at Indian Immunologicals Limited.

The Rx–Outcomes Dichotomy: India Has Iron Tablets. Why Does Anaemia Persist?

10 Years of Pharma M&A — Who’s Really Benefited?

What’s Killing Patients? Cancer or Rigged Drug Prices?

Newsletter